Appointments at Premier Research, Porsolt and BioStorage – People on the move

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Premier Research, Porsolt and BioStorage.

Premier Research Group has appointed Charlene Sanders as vice president (VP), global regulatory affairs and pediatric strategic consulting. Sanders has previously worked at Merck & Co, Duramed Research and Sankyo Pharma Development during a 15 year career.

David Pushett has joined Porsolt as director of global business development. Pushett has worked in biotech for 15 years at companies including periods at PsychoGenics and MindGenix.

Clinical Trials of America has named Pamela Pannier as its clinical operations director. During an 18 year career in clinical research Pannier has worked at Advanced Clinical Research and Coordinators Plus.

Gregory Swanberg has been hired by BioStorage Technologies to serve as its CEO. Swanberg replaces company co-founder John Mills who remains as chairman of the board. Before joining BioStorage Swanberg worked at Pfizer, Merck, Genentech, Novartis and Eli Lilly.

Logistics service provider Longistics has promoted Berry Petty Jr to the positions of VP and general manager of the transportation division. Petty joined Longistics in 1998 and previously worked as a controller.

Richard Hawkins, the founder of contract research organisation (CRO) Pharmaco, has joined the board of directors at Savara. In addition to Pharmaco Hawkins has worked at Sensus Drug Development, Covance Biotechnology Services and LoopOne.

Business service provider DDN has appointed Steve Schommer as VP, logistics and supply chain. Schommer worked at UPS for 25 years before taking the position of CEO at Wavechange Logistics.

Steven Klosk, president and CEO of Cambrex, has been awarded for ‘Embracing Innovation’, both personally and professionally, by the New York Law School.

ShangPharma has named Benson Tsang as a member of its board of directors and audit committee. Kevin Penghui Chen, chief financial and operating officer at ShangPharma, will resign as a member of the audit committee but remain on the board.